RALEIGH, N.C., Aug. 27, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the company will be hosting an investor and analyst event and simultaneous webcast on Friday, September 5, 2014. The event is scheduled for 12-2 pm ET in New York City.
At this event, BDSI senior management will discuss the commercialization and launch plan for BUNAVAIL and provide updates on the BEMA ® Buprenorphine chronic pain and Clonidine Topical Gel programs. Nationally recognized addiction experts will discuss the growing epidemic of opioid dependence and the opportunity for BUNAVAIL. Investors and analysts wishing to attend are requested to RSVP to: email@example.com A live webcast will be available on the company's website www.bdsi.com. About BioDelivery Sciences International BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA ®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's development strategy focuses on utilization of the FDA's 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics. BDSI's particular area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence.